AbbVie (NYSE: ABBV), announced on 5/1/18 that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-... read more
AbbVie (NYSE: ABBV), announced on 5/1/18 that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-... read more
Medtronic plc (NYSE:MDT) announced on 5/1/18 that the U.S. Food and Drug Administration (FDA) has granted premarket approval for Medtronic's Deep Brain Stimulation (DBS) therapy as adjunctive... read more
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced long-term preclinical efficacy data... read more
On April 13, 2018 the 4th U.S. Circuit Court of Appeals struck down a Maryland law that allowed the state attorney general to sue drugmakers who raised prices on generic or off-patent drugs by... read more
Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab... read more